MURAL ONCOLOGY Trademark

Trademark Overview


On Wednesday, May 10, 2023, a trademark application was filed for MURAL ONCOLOGY with the United States Patent and Trademark Office. The USPTO has given the MURAL ONCOLOGY trademark a serial number of 97929534. The federal status of this trademark filing is EXAMINERS AMENDMENT - MAILED as of Thursday, June 27, 2024. This trademark is owned by Alkermes Pharma Ireland Limited. The MURAL ONCOLOGY trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical prep...

Therapeutic proteins for use in the manufacture of pharmaceutical preparations

Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment

Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data...
mural oncology

General Information


Serial Number97929534
Word MarkMURAL ONCOLOGY
Filing DateWednesday, May 10, 2023
Status647 - EXAMINERS AMENDMENT - MAILED
Status DateThursday, June 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of the word "MURAL" in stylized, capitalized font positioned above the word "ONCOLOGY" in stylized, capitalized font within the image of an incomplete circle that surrounds the wording and has a small break or opening to the left of the aforementioned text.
Goods and ServicesBiopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesTherapeutic proteins for use in the manufacture of pharmaceutical preparations
Goods and ServicesProviding educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment
NOT AVAILABLEONCOLOGY
Goods and ServicesResearch and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, and fusion proteins, used to treat cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and products development for others in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals for use in the treatment of cancer and cancer-related disorders; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development for others of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical products development for others in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and products development for others in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateTuesday, April 23, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 8, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 8, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 8, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMURAL ONCOLOGY, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressWALTHAM, MA 02451

Party NameAlkermes Pharma Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDublin 4
IE

Trademark Events


Event DateEvent Description
Saturday, May 13, 2023NEW APPLICATION ENTERED
Monday, January 29, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 8, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 9, 2023NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, January 23, 2024ASSIGNED TO EXAMINER
Monday, January 29, 2024NON-FINAL ACTION WRITTEN
Monday, January 29, 2024NON-FINAL ACTION E-MAILED
Tuesday, April 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 28, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, April 23, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, April 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 11, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, June 11, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, June 11, 2024EXAMINER'S AMENDMENT ENTERED
Tuesday, June 11, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, June 27, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, June 27, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, June 27, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, June 27, 2024EXAMINER'S AMENDMENT ENTERED